PROPANAMIDE, N-(4-(2,2-DIMETHYL-1-OXOPROPYL)-5-((((2-(ETHYLAMINO)ETHYL)SULFONYL)AMINO)METHYL)-4,5-DIHYDRO-5-PHENYL-1,3,4-THIADIAZOL-2-YL)-2,2-DIMETHYL-, (5R)-
Cancer of Head and Neck
Eli Lilly and CompanySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
142 Active assets in the Cancer of Head and Neck cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Instituto Nacional de Cancer, Brazil | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II ImmunityBio, Inc. | Phase 3 | BB |
LIDOCAINE Instituto Nacional de Cancer, Brazil | Phase 3 | BB |
Carboplatin Rapa Therapeutics LLC | Phase 3 | BB |
Cetuximab Pfizer | Phase 3 | BB |
View all 50 →
Same molecule, other indications
PROPANAMIDE, N-(4-(2,2-DIMETHYL-1-OXOPROPYL)-5-((((2-(ETHYLAMINO)ETHYL)SULFONYL)AMINO)METHYL)-4,5-DIHYDRO-5-PHENYL-1,3,4-THIADIAZOL-2-YL)-2,2-DIMETHYL-, (5R)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →